HUTCHMED (China) Limited (HCM)

American Depository Receipt

Sell: $13.50|Buy: $13.55|Change: 0.20 (1.50%)

Open

$13.34

Previous close

$13.35

Trade high

$13.59

Volume

71,120

Year high

$19.50

Year low

$11.505

Dividend yield

–

Market capitalisation

$2.33 bn

P/E ratio

5.11

ISIN

US44842L1035

This share can be held in a Dealing account SIPP

Share price

Performance 19/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
HUTCHMED (China) Limited	+ 1.50
More...

Company profile

HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolioof several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.